| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14787210.4.5.795 |
| P698 | PubMed publication ID | 17140356 |
| P50 | author | Ian G. Barr | Q41045800 |
| Aeron C. Hurt | Q42216629 | ||
| P2093 | author name string | Hui-Ting Ho | |
| P2860 | cites work | Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic | Q22306097 |
| Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo | Q27477604 | ||
| The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor | Q27642166 | ||
| Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza | Q28201381 | ||
| Re-emergence of fatal human influenza A subtype H5N1 disease | Q28247143 | ||
| Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors | Q28263525 | ||
| Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern | Q28275022 | ||
| Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses | Q28353147 | ||
| Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. | Q28369317 | ||
| Rational design of potent sialidase-based inhibitors of influenza virus replication | Q29616647 | ||
| Oseltamivir resistance during treatment of influenza A (H5N1) infection | Q29618722 | ||
| Potential impact of antiviral drug use during influenza pandemic | Q30232931 | ||
| Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir | Q30306773 | ||
| Developing vaccines against pandemic influenza | Q30329367 | ||
| Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. | Q30350180 | ||
| Avian flu: isolation of drug-resistant H5N1 virus. | Q30351638 | ||
| Antiviral resistance in influenza viruses--implications for management and pandemic response. | Q30353085 | ||
| Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors | Q30438502 | ||
| Recovery of drug-resistant influenza virus from immunocompromised patients: a case series | Q30439558 | ||
| Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine | Q30448585 | ||
| Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults | Q30451307 | ||
| Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics | Q30451349 | ||
| Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. | Q30452889 | ||
| Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. | Q30453005 | ||
| In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication | Q30453074 | ||
| Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus | Q30472691 | ||
| Oral oseltamivir treatment of influenza in children. | Q32064242 | ||
| Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. | Q33243576 | ||
| Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations | Q33804210 | ||
| Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. | Q33813321 | ||
| The molecular basis of the specific anti-influenza action of amantadine | Q33931939 | ||
| Resistance of influenza viruses to neuraminidase inhibitors--a review. | Q33993985 | ||
| Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility | Q34077100 | ||
| Position statement: global neuraminidase inhibitor susceptibility network | Q34294358 | ||
| Neuraminidase inhibitors for influenza | Q34455162 | ||
| The M2 proton channels of influenza A and B viruses | Q34483647 | ||
| Inhibition of influenza virus production in virus-infected mice by RNA interference | Q34514513 | ||
| Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient | Q34648838 | ||
| Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en | Q35857200 | ||
| Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. | Q35882160 | ||
| Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection | Q36866575 | ||
| Influenza: diagnosis, management, and prophylaxis | Q36885662 | ||
| The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines | Q39303124 | ||
| Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors | Q39577999 | ||
| Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs | Q39626221 | ||
| Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir | Q39671211 | ||
| Frequency of Amantadine-Resistant Influenza A Viruses during Two Seasons Featuring Cocirculation of H1N1 and H3N2 | Q39751284 | ||
| Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. | Q39781147 | ||
| Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. | Q40045076 | ||
| Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. | Q40261107 | ||
| Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants | Q40308685 | ||
| Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. | Q40435698 | ||
| Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. | Q40467433 | ||
| The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. | Q40579225 | ||
| Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets | Q40580607 | ||
| In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir | Q40911739 | ||
| Low incidence of rimantadine resistance in field isolates of influenza A viruses | Q40930290 | ||
| The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en | Q41027402 | ||
| Mechanism of action of T-705 against influenza virus | Q41091905 | ||
| Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme | Q41154536 | ||
| Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en | Q41258352 | ||
| Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en | Q41258522 | ||
| Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir | Q43210983 | ||
| A single sequence change destabilizes the influenza virus neuraminidase tetramer | Q43971312 | ||
| Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo | Q44025966 | ||
| Resistant influenza A viruses in children treated with oseltamivir: descriptive study | Q45036693 | ||
| Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets | Q45101875 | ||
| ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). | Q45153220 | ||
| Emergence and transmission of amantadine-resistant influenza A in a nursing home. | Q45280919 | ||
| Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient | Q45728987 | ||
| Anti-virals for influenza virus infection | Q46820708 | ||
| Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States | Q46925884 | ||
| Influenza | Q54079365 | ||
| The impact of influenza epidemics on mortality: introducing a severity index. | Q54731473 | ||
| High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza | Q73570981 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 795-805 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors | |
| P478 | volume | 4 |
| Q38209673 | A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade |
| Q60638540 | Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections |
| Q58066873 | Anti-influenza therapy: the emerging challenge of resistance |
| Q38401883 | Antiviral treatment of influenza in South Korea |
| Q34120005 | Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model |
| Q43800842 | Development and implementation of influenza a virus subtyping and detection of genotypic resistance to neuraminidase inhibitors |
| Q30370409 | Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance. |
| Q90663218 | Evolutionary, genetic, structural characterization and its functional implications for the influenza A (H1N1) infection outbreak in India from 2009 to 2017 |
| Q28483631 | Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study |
| Q34019902 | Full genome comparison and characterization of avian H10 viruses with different pathogenicity in Mink (Mustela vison) reveals genetic and functional differences in the non-structural gene. |
| Q37082747 | Genetic strategy to prevent influenza virus infections in animals |
| Q45360594 | Identification of influenza virus inhibitors targeting NS1A utilizing fluorescence polarization-based high-throughput assay |
| Q37392896 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| Q89706221 | Influenza and antiviral resistance: an overview |
| Q24645944 | Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1) |
| Q35930657 | Intersubtype Reassortments of H5N1 Highly Pathogenic Avian Influenza Viruses Isolated from Quail |
| Q30352689 | Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus. |
| Q90668502 | Molecular simulation study of the binding mechanism of [α-PTi2W10O40]7- for its promising broad-spectrum inhibitory activity to FluV-A neuraminidase |
| Q28548477 | Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses |
| Q37146912 | Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam, 2009-2012. |
| Q30382944 | Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. |
| Q30420391 | Pandemism of swine flu and its prospective drug therapy |
| Q34800749 | Phylogenetic analysis of neuraminidase gene of H9N2 avian influenza viruses isolated from chicken in Iran during 2010-2011. |
| Q48058751 | Sequence analysis of the neuraminidase genes of avian influenza A viruses isolated from live bird markets in the United States |
| Q92826332 | Structural insight into RNA synthesis by influenza D polymerase |
| Q38699365 | Synthesis and In Vitro Anti-Influenza Virus Evaluation of Novel Sialic Acid (C-5 and C-9)-Pentacyclic Triterpene Derivatives |
| Q21261835 | Systematic review of influenza resistance to the neuraminidase inhibitors |
| Q30387832 | Targeting pandemic influenza: a primer on influenza antivirals and drug resistance |
| Q40577964 | The inhibitory effect of dehydroepiandrosterone and its derivatives against influenza A virus in vitro and in vivo |
| Q36993551 | Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection |
| Q30352557 | Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic. |
| Q30415228 | Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic |
| Q40277337 | Virological Surveillance of Influenza A Subtypes Isolated in 2014 from Clinical Outbreaks in Canadian Swine |
| Q41095623 | Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring |
Search more.